ELUTNCMHealthcare·Medical Devices#103 in industry

Elutia Inc.

Reports in 10d· 2026-05-07

+2.0% · 90d

$1.02

-0.05 (-4.67%)

After-Hours $1.02(+0.00)

News

(2)

April 2026

Apr 22, 20265 days agoARSHealthcare

ELUTIA (ELUT) submits ARS filing; report content remains unavailable for review

ELUTELUTIA INC.

As an expert financial analyst and educator, I am fully prepared to generate a comprehensive, structured, and highly educational summary following all your strict guidelines, including the required formatting, section depth, and pedagogical tone. However, the source document provided only contains

Read summaryView on SEC EDGAR

Apr 22, 20265 days agoDEF 14AHealthcare

ELUT Proxy Details Votes on Directors, Auditors, and Incentive Compensation Plans

ELUTELUTIA INC.

# 🗳️ What This Document Is This is a **Proxy Statement (Schedule 14A)**. Think of this document as an official voter guide for Elutia Inc.'s Annual Meeting of Stockholders. 📚 It doesn't contain financial performance numbers, but rather governance information and key proposals that stockholders mus

Read summaryView on SEC EDGAR

Key Data

Market Cap$47.5M

Open$1.05

Prev Close$1.07

Day Range$1.02 – $1.10

52W Range$0.50 – $2.64

Volume92,166

P/E (TTM)—

EPS$-0.64

Dividend Yield—

Beta0.71

Profit Margin434.23%

Revenue Growth16.20%

Price Target$5.00(+390.2%)

Next Earnings2026-05-07(10d)

Analyst Ratings

Strong Buy1 analysts

Buy 1Hold 0Sell 0

About

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.

Healthcare · Medical Devices

25 employees

elutia.com